Quality of life in patients with osteoarthrosis of knee joints and aberrant production of melatonin and galectin-3


  • O.V. Humeniuk
Keywords: melatonin, 6-sulfatoxymelatonin, galectin-3, osteoarthrosis, knee joint, SF-36, quality of life.

Abstract

The study covered the indicators of quality of life in patients with osteoarthrosis of knee joints with aberrant production of melatonin and galectin-3. In patients with OA, the reduction of 6-sulfatexymelatonin urine excretion was associated with a moderate decline in the quality of life indicators at the account of SF-36 psychological health component. Instead, raising the blood galectin-3 concentration in patients with OA was associated with a significant decrease of the physical component and a less pronounced decline of the SF-36 psychological health component. Blood galectin-3 and 6-sulfatexymelatonin excretion levels appeared to have an inverse associative dependence.

References

1. Voloshyna, L. O., & Smiian, S. I. (2016). Osteoartroz, poli- ta komorbidnist: vikovi, henderni, prohnostychni y likuvalno-profilaktychni aspekty: dani tryrichnoho prospektyvnoho doslidzhennia. Ukrainskyi revmatolohichnyi zhurnal, 4 (66), 51-57. [in Ukrainian].

2. Karavaeva, S. A. (2002). Diagnostika i osobennosti klinicheskogo techeniya nekroticheskogo enterokolita u detej. Vestnik hirurgii, 4, 41-46. [in Russian].

3. Karpova, I. Yu., & Parshikov, V. V. (2011). Nekroticheskij enterokolit u novorozhdennyh. Detskaya hirurgiya, 6, 47-49. http://therapy.irkutsk.ru/doc/sf36a.pdf. [in Russian].

4. Kovalenko, V. M., & Bortkevych, V. M. (2011). Osteoartroz i bil: stan problemy. Bol. Sustavы. Pozvonochnyk, 1 (1). Vziato z http://www.mif-ua.com/archive/article/16189. [in Ukrainian].

5. Alkan, B. M., Fidan, F., Tosun, A., & Ardıçoğlu, O. (2014). Quality of life and self-reported disability in patients with knee osteoarthritis. Mod. Rheumatol., 24 (1), 166-171.

6. Altman, R. D. (1991). Criteria for the classification of clinical osteoarthritis. J. Rheumatology, 18 (27), 10-12.

7. de Boer, R. A., van Veldhuisen, D. J., Gansevoort, R. T., Muller, K. AC., van Gilst, W. H.,…..van der Harst. (2012). The fibrosis marker galectin-3 and outcome in the general population. J. Intern Med, 272, 55-64.

8. Dong, R., Zhang, M., & Hu, Q. (2018). Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy. Int. J. Mol. Med., 41 (2), 599-614.

9. Emet, M., Ozcan, H., Ozel, L., Yayla, M., Halici, Z., & Hacimuftuogly, A. (2016). A review of melatonin, its receptors and drugs. Eurasian J. Med., 48, 135-141.

10. Garratt, A. M., & Stavem, K. (2017). Measurement properties and normative data for the Norwegian SF-36: results from a general population survey. Health and Quality of Life Outcomes, 15, Р.51 Retrieved from https://doi.org/10.1186/s12955-017-0625-9.

11. Hardeland, R. (2012). Neurobiology, pathophysiology, and treatment of melatonin deficiency and dysfunction. Scientific World Journal, 2012, 640389. doi: 10.1100/2012/640389.

12. Hu, Y., Yéléhé-Okouma, M., & Ea, H. K. (2017). Galectin-3: A key player in arthritis. Joint Bone Spine, 84 (1), 15-20.

13. Jenwitheesuk, A., Nopparat, C., & Mukda, S. (2014). Melatonin regulates aging and neurodegeneration through energy metabolism, epigenetics, autophagy and circadian rhythm pathways. Int. J. Mol. Sci., 15 (9), 16848-16884.

14. Parmelee, P.A., Tighe, C. A., & Dautovich N. D. (2015). Sleep disturbance in osteoarthritis: linkages with pain, disability and depressive symptoms. Arthritis Care & Research, 67 (3), 358-365.

15. Qiao, L., & Shen, W. (2014). The effect of melatonin on galectin-3, TNF-α, and IL-1β in newborn rats brain damage after hypoxia-ischemia and its impact on long-term behavior. Journal of Clinical Pediatrics, 32 (5), 480-484.

16. Sanchis-Gomar, F., Santos-Lozano, A., & Pareja-Galeano, H. (2016). Galectin-3, osteopontin and successful aging. Clin. Chem. Lab. Med., 54 (5), 873-877.

17. Schernhammer, E. S., Kroenke, C. H., Dowsett, M., Folkerd, E., & Hankinson, S. E. (2006). Urinary 6-sulfatoxymelatonin levels and their correlations with lifestyle factors and steroid hormone levels. J. Pineal.Res, 40 (2), 116-124.

18. Smith, M. T., Finan, P. H., Buenaver, L. F., Robinson, M., Hague, U., Guain, A,…..Leoutsakis, L. (2015). Cognitive-behavioral therapy for insomnia in knee osteoarthritis: a randomized, double-blind, active placebo-controlled clinical trial. Arthritis Rheumatol, 67 (5), 1221-1233.

19. Zhang, W., Doherty, M., Peat, G., Biesma-Zeinstra, M. A., Arden, N. K., Bresnihan, B.,…..Bijlsma J. W. (2010). EULAR evidence-based recommendations for the diagnosis of knee osteoarthritis. Ann. Rheum. Dis., 69 (3), 483-489.
Published
2017-10-27
How to Cite
Humeniuk, O. (2017). Quality of life in patients with osteoarthrosis of knee joints and aberrant production of melatonin and galectin-3. Biomedical and Biosocial Anthropology, (29), 140-144. Retrieved from https://bba-journal.com/index.php/journal/article/view/307